{"preliminary_commentary":{"by_channel":{"podcast":12,"x_thread":11,"youtube":9},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02864251\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"CheckMate 722","nct_id":"NCT02864251","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-722-nct02864251. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CheckMate722","arms":[{"description":null,"label":"Nivolumab+Platinum doublet chemotherapy","type":"EXPERIMENTAL"},{"description":"Enrollment is closed for this arm","label":"Nivolumab + Ipilimumab","type":"EXPERIMENTAL"},{"description":null,"label":"Platinum doublet chemotherapy","type":"ACTIVE_COMPARATOR"}],"collaborators":["Ono Pharmaceutical Co., Ltd."],"completion_date":{"date":"2022-10-17","type":"ACTUAL"},"conditions":["Non-Small-Cell Lung Carcinoma"],"enrollment":{"count":367,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["Opdivo","BMS-936558"],"type":"BIOLOGICAL"},{"name":"Ipilimumab","otherNames":["Yervoy","BMS-734016"],"type":"BIOLOGICAL"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2023-09-28","lead_sponsor":"Bristol-Myers Squibb","official_title":"Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor Therapy","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2022-01-20","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)","timeFrame":"From randomization to the date of first documented tumor progression or death (approximately 58 months)"}],"references":[{"citation":"Mok T, Nakagawa K, Park K, Ohe Y, Girard N, Kim HR, Wu YL, Gainor J, Lee SH, Chiu CH, Kim SW, Yang CT, Wu CL, Wu L, Lin MC, Samol J, Ichikado K, Wang M, Zhang X, Sylvester J, Li S, Forslund A, Yang JC. Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722. J Clin Oncol. 2024 Apr 10;42(11):1252-1264. doi: 10.1200/JCO.23.01017. Epub 2024 Jan 22.","pmid":"38252907","type":"DERIVED"}],"start_date":{"date":"2017-03-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy","url":"https://clinicaltrials.gov/study/NCT02864251"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-722-nct02864251"}